Keyphrases
Denmark
100%
8-oxoguanine
84%
Type 2 Diabetes Mellitus (T2DM)
72%
Oxidative Stress
59%
Confidence Interval
57%
Oxidative DNA Damage
51%
Type 2 Diabetic Patients
46%
8-oxo-7,8-dihydroguanosine
44%
Placebo
41%
National Cohort Study
41%
Paracetamol
41%
Glucagon-like
41%
Glucose-dependent Insulinotropic Polypeptide
40%
Pharmacokinetics
36%
Urinary Excretion
34%
Antipyrine
33%
Metabolism
28%
Odds Ratio
27%
RNA Oxidation
27%
N-acetylcysteine
26%
Acetaminophen
26%
During Pregnancy
26%
Poisoning
25%
Randomized Clinical Trial
24%
Oxidative Stress Markers
24%
Liver
23%
DNA Damage
22%
Paracetamol Overdose
21%
Randomized Controlled Trial
21%
Metformin
21%
Placebo-controlled
21%
Randomized Placebo-controlled Trial
20%
Randomized Double-blind
20%
Meta-analysis
20%
Polypharmacy
20%
Glucagon
19%
Hemoglobin A1c (HbA1c)
19%
Antipsychotics
18%
Poison Control Centers
18%
Capital Region
18%
Hazard Ratio
18%
Vitamin C
18%
DNA Oxidation
17%
Adverse Events
17%
Medication Review
17%
RNA Damage
17%
A1 Receptor
17%
Vitamin E
16%
Randomized Trial
16%
Healthy Individuals
16%
Metronidazole
16%
High Dose
16%
Smokers
16%
Blood Pressure
15%
COVID-19
15%
Adverse Effects
15%
Hospitalized Patients
15%
Glucose-lowering Drugs
15%
Urinary Markers
15%
Plasma Concentration
14%
Cytochrome P450 1A2 (CYP1A2)
14%
Type 1 Diabetes Mellitus (T1DM)
14%
Antioxidant
14%
Polymorphism
14%
Glutathione
14%
Ascorbic Acid
13%
Adverse Drug Reaction
13%
Nucleic Acid Oxidation
13%
Glucose-dependent Insulinotropic Polypeptide Receptor
13%
Hospitalization
13%
Type I Diabetes
13%
DNA Repair
12%
Copenhagen
12%
Healthy Controls
12%
Systematic Meta-analysis
12%
Register-based
12%
Blood Samples
12%
Oxidative Damage
12%
Obesity
12%
Prescription Drugs
12%
Drug Interactions
12%
Rat Liver
12%
Cystic Fibrosis
12%
Colon
12%
Genotype
11%
Cytochrome P450 2D6 (CYP2D6)
11%
Selective Serotonin Reuptake Inhibitors
11%
Bipolar Disorder
11%
Activated Charcoal
11%
Receptor Agonist
11%
Liraglutide
11%
Register Study
11%
Medication Use
11%
Type 2 Diabetes Prevention
11%
Carboxylesterase 1 (CES1)
10%
Oxazepam
10%
No Significant Difference
10%
Gastric Emptying
10%
University Hospital
10%
Guanine
10%
Pharmacology, Toxicology and Pharmaceutical Science
Paracetamol
76%
Toxic Injury
73%
Non Insulin Dependent Diabetes Mellitus
73%
Cohort Study
68%
8 Hydroxydeoxyguanosine
64%
Placebo
61%
Pharmacokinetics
50%
Adverse Event
43%
Disease
39%
Biological Marker
30%
Gastric Inhibitory Polypeptide
29%
Ascorbic Acid
28%
Malignant Neoplasm
28%
Acetylcysteine
26%
Prevalence
24%
Phenazone
23%
Antioxidant
23%
Congenital Malformation
22%
Elimination
22%
Adverse Drug Reaction
20%
Glutathione
20%
Nucleic Acid
20%
Poison Control Centers
20%
Glucagon-Like Peptide-1
19%
Pharmacotherapy
19%
Mouse
18%
Normal Human
18%
Symptom
16%
Polypharmacy
16%
Side Effect
15%
Pharmacodynamics
14%
Typical Antipsychotic
14%
Infection
14%
Metformin
14%
Randomized Controlled Trial
14%
Cardiovascular Disease
13%
Drug Metabolism
13%
Hepatotoxicity
13%
Metronidazole
13%
Gastric Inhibitory Polypeptide Receptor
12%
Antipsychotic
12%
Creatinine
12%
Asthma
12%
CYP1A2
12%
Alpha Tocopherol
11%
Bile Acid
11%
Clinical Trial
11%
High Performance Liquid Chromatography
11%
Drug Information
11%
Guanosine
11%
Oxazepam
11%
Selective Serotonin Reuptake Inhibitor
11%
Chronic Obstructive Lung Disease
10%
Glucagon Like Peptide 1 Receptor Agonist
10%
Obesity
10%
CYP2D6
10%
Cystic Fibrosis
9%
Observational Study
9%
Analgesic Agent
9%
Guanine
9%
Isradipine
9%
Cytochrome
9%
Combination Therapy
9%
Deoxyguanosine
9%
Cytochrome P450
9%
Nucleoside
9%
CYP2C19
9%
Hemoglobin A1c
9%
Defined Daily Dose
9%
Heart Failure
9%
Spontaneous Abortion
9%
Metoprolol
9%
Receptor Antagonist
9%
Randomized Clinical Trial
8%
Tramadol
8%
Drug-Drug Interaction
8%
Coronavirinae
8%
Inflammation
8%
Methylphenidate
8%
Big Blue Rat
8%
Antidepressant
8%
Liraglutide
8%
Drug Screening
8%
Opiate
8%
Ischemic Heart Disease
8%
Genotoxicity
8%
Medication Error
8%
Reactive Oxygen Metabolite
7%
Fluvoxamine
7%
Benzodiazepine
7%
Antibiotic Agent
7%
Bioavailability
7%
Hydrocortisone
7%
Low Density Lipoprotein Cholesterol
7%
All Cause Mortality
7%
Cimetidine
7%
Activated Carbon
7%
Case-Control Study
7%
Glucagon-Like Peptide 1 Receptor
7%
Liver Cirrhosis
7%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
61%
Drug Therapy
40%
Cohort Analysis
38%
Placebo
34%
Gastric Inhibitory Polypeptide
29%
Glucagon Like Peptide 1
22%
Patient with Type 2 Diabetes
21%
Adverse Event
21%
Glycon
20%
Disease
20%
Oxidative Stress
19%
Systematic Review
17%
Randomized Clinical Trial
17%
Hazard Ratio
15%
Infusion
15%
Blood Pressure
15%
Diabetes
14%
8 Hydroxydeoxyguanosine
14%
Urinary System
13%
Cardiovascular Disease
13%
COVID-19
13%
Randomized Controlled Trial
13%
Meta-Analysis
12%
Malignant Neoplasm
12%
Urinary Excretion
12%
Medicine
12%
Biological Marker
11%
Hemoglobin A1c
11%
Ascorbic Acid
10%
DNA Damage
10%
Antioxidant
10%
Odds Ratio
10%
Lifestyle Intervention
10%
Supplementation
9%
Prevalence
9%
Symptom
9%
Body Mass Index
9%
Nucleic Acid
9%
Obesity
9%
Food Intake
9%
Cardiovascular System
9%
Paracetamol
8%
Glucagon
8%
DNA Repair
8%
Adverse Drug Reaction
8%
Breast Cancer
8%
Post-Hoc Analysis
8%
Breast Implant
8%
Glucagon-Like Peptide-1 Agonist
7%
Glycemic Control
7%
Congenital Malformation
7%
Androgen
7%
Hypoglycemia
7%
Exercise
7%
Spontaneous Abortion
7%
Adolescent
7%
Antibiotics
7%
Gut
7%
Infection
7%
General Practitioner
7%
First Trimester Pregnancy
7%
Insulin Dependent Diabetes Mellitus
7%
Cystic Fibrosis
7%
Anabolic Agent
6%
Childbirth
6%
Bile Acid
6%
Chronic Obstructive Pulmonary Disease
6%
Physical Activity
6%
Cosmetics
6%
Observational Study
6%
Body Weight
6%
Clinical Trial
6%
Receptor
6%
Cross Sectional Study
6%
Arm
6%
Low Density Lipoprotein Cholesterol
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Opiate
6%
Glucose Metabolism
6%
Polypharmacy
6%
Secretion (Process)
6%
Sodium Intake
6%
Alpha Tocopherol
6%
Hydrocortisone
6%
Receptor Antagonist
6%
Emergency Department
5%
Incretin
5%
Diabetes Mellitus
5%
Health Care
5%
Intensive Care Unit
5%
Triacylglycerol
5%
Outpatient
5%
Cell Function
5%
Psoriasis
5%
Knee Arthroplasty
5%
Coronary Artery Disease
5%
Hip Arthroplasty
5%
B-Cell Chronic Lymphocytic Leukemia
5%
Ischemic Heart Disease
5%
Stomach Emptying
5%